People · Operator
Named in public records as an officer, director or promoter · active 2012–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OriGene Technologies, Inc. | — | Biotechnology | Series B | $38.6M | $676.8M | 2012 |
Gene Dove at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gene Dove on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Quan Zhou | 1 | 5 |
| Wei-Wu He | 1 | 4 |
| James Hu | 1 | 3 |
| Anil Gupta | 1 | 2 |
| Youmin Shu | 1 | 1 |
| Rich Hamer | 1 | 1 |
| Tony Su | 1 | 1 |
| Tom Bluth | 1 | 1 |
| Lanchun Duan | 1 | 1 |
| Ellen Shih | 1 | 1 |
| Karl Kovacs | 1 | 1 |
| Amy Tang | 1 | 1 |
| Beatrice Leung | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.